Plus, more than 66 percent: Biotech stocks are in the Corona of a crisis in demand

Around the globe, tens of companies, biotech companies, institutions and universities are working on vaccines and drugs against the Coronavirus. In this country

Plus, more than 66 percent: Biotech stocks are in the Corona of a crisis in demand

Around the globe, tens of companies, biotech companies, institutions and universities are working on vaccines and drugs against the Coronavirus. In this country, Curevac and the to the American Nasdaq-listed Biontech SE of Mainz have drawn recently a lot of attention. As the crisis in General, the impact on the biotech industry and, above all, its listed companies, shows the survey "Biotech Barometer" of the European stock exchange Euronext, which is regularly placed.

Ilka Kopplin

editor in the economy.

F. A. Z.

Thus, in the course of a total of 61 on the Euronext-listed biotech companies increased in the first half of this year, an average of 66.8 percent. Noteworthy are French companies, whose share has increased rates in this period to an average of 85.3 per cent, while Dutch is a decline of 17.3 percent, and Belgian companies had to accept a Minus of 1.5 percent.

the courses through the Corona of a crisis to be driven, shows an other comparison: The share prices of 14 companies that develop against the Coronavirus vaccinations, medications or diagnostic products, have since the beginning of the year, on average, 233,7 percent, while the remaining 47 companies have recorded a comparatively moderate increase from an average of 17.1 percent.

Plus in 1983 percentage

Extreme outliers, the French diagnostics company Novacyt with a Plus of 1983 percent or the Norwegian biotech company Bergenbio, its price has increased by 532 percent are. At the beginning of June Bergenbio announced, to test the drug Bemcentinib in a clinical study of Phase II against the Coronavirus. Also, the course of the French drug developer's Biophytis to put in the first half of the year, at least 380 percent.

in Addition, the market capitalization of biotech companies in the first six months of the year shows a positive Trend: Overall, they rose by EUR 4.5 billion to a record high of around 29 billion euros. On average, the market capitalization of the 61 companies rose from 273 million euros at the beginning of last year to 475 million at the beginning of 2020.

However, the survey should not obscure the fact that biotech companies often have to go to the American Nasdaq, because they expected a better investor environment. So, too, Biontech, and Morphosys are, for example, on the American technology stock exchange listed. Also from the tübingen-based company Curevac, it States that it wants to go to the stock exchange.

Updated Date: 08 July 2020, 16:20

You need to login to comment.

Please register or login.

RELATED NEWS